CrossFirst Bankshares, Inc.

NasdaqGS:CFB Stok Raporu

Piyasa değeri: US$774.0m

CrossFirst Bankshares Gelecekteki Büyüme

Future kriter kontrolleri 2/6

CrossFirst Bankshares is forecast to grow earnings and revenue by 9.6% and 9.7% per annum respectively. EPS is expected to grow by 9% per annum. Return on equity is forecast to be 9.9% in 3 years.

Anahtar bilgiler

9.6%

Kazanç büyüme oranı

9.0%

EPS büyüme oranı

Banks kazanç büyümesi10.4%
Gelir büyüme oranı9.7%
Gelecekteki özkaynak getirisi9.9%
Analist kapsamı

Low

Son güncelleme30 Oct 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

Here's Why Shareholders May Want To Be Cautious With Increasing CrossFirst Bankshares, Inc.'s (NASDAQ:CFB) CEO Pay Packet

May 08
Here's Why Shareholders May Want To Be Cautious With Increasing CrossFirst Bankshares, Inc.'s (NASDAQ:CFB) CEO Pay Packet

Is Now The Time To Put CrossFirst Bankshares (NASDAQ:CFB) On Your Watchlist?

Jan 25
Is Now The Time To Put CrossFirst Bankshares (NASDAQ:CFB) On Your Watchlist?

CrossFirst Bankshares GAAP EPS of $0.35 beats by $0.01, revenue of $53.48M beats by $0.18M

Oct 17

CrossFirst Bankshares GAAP EPS of $0.31 misses by $0.01, revenue of $50.9M beats by $0.9M

Jul 18

Here's Why We Think CrossFirst Bankshares (NASDAQ:CFB) Is Well Worth Watching

Nov 30
Here's Why We Think CrossFirst Bankshares (NASDAQ:CFB) Is Well Worth Watching

Here's Why We Think CrossFirst Bankshares (NASDAQ:CFB) Is Well Worth Watching

Jul 27
Here's Why We Think CrossFirst Bankshares (NASDAQ:CFB) Is Well Worth Watching

CrossFirst Bankshares names new CFO

Jun 21

Should CrossFirst Bankshares (NASDAQ:CFB) Be Disappointed With Their 19% Profit?

Mar 06
Should CrossFirst Bankshares (NASDAQ:CFB) Be Disappointed With Their 19% Profit?

CrossFirst Bankshares, Inc. 2020 Q4 - Results - Earnings Call Presentation

Feb 01

CrossFirst Bankshares, Inc. Recorded A 41% Miss On Revenue: Analysts Are Revisiting Their Models

Jan 30
CrossFirst Bankshares, Inc. Recorded A 41% Miss On Revenue: Analysts Are Revisiting Their Models

Could The CrossFirst Bankshares, Inc. (NASDAQ:CFB) Ownership Structure Tell Us Something Useful?

Jan 04
Could The CrossFirst Bankshares, Inc. (NASDAQ:CFB) Ownership Structure Tell Us Something Useful?

What Type Of Returns Would CrossFirst Bankshares'(NASDAQ:CFB) Shareholders Have Earned If They Purchased Their SharesYear Ago?

Nov 30
What Type Of Returns Would CrossFirst Bankshares'(NASDAQ:CFB) Shareholders Have Earned If They Purchased Their SharesYear Ago?

Kazanç ve Gelir Büyüme Tahminleri

NasdaqGS:CFB - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
TarihGelirKazançlarSerbest Nakit AkışıFaaliyetlerden NakitAvg. Analist Sayısı
12/31/202630291N/AN/A1
12/31/202528384N/AN/A3
12/31/202426177N/AN/A2
9/30/2024243749599N/A
6/30/2024237718793N/A
3/31/2024233688795N/A
12/31/2023231669099N/A
9/30/2023225618290N/A
6/30/20232186197103N/A
3/31/2023209618690N/A
12/31/2022199627880N/A
9/30/2022201708385N/A
6/30/2022201746870N/A
3/31/202219574111113N/A
12/31/2021186698788N/A
9/30/2021165579092N/A
6/30/2021147448186N/A
3/31/2021127215258N/A
12/31/2020115137480N/A
9/30/202010246772N/A
6/30/202010367780N/A
3/31/2020114237576N/A
12/31/2019120287374N/A
9/30/2019129397173N/A
6/30/2019122343163N/A
3/31/2019113251754N/A
12/31/201810317346N/A
12/31/2017664N/A23N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: CFB's forecast earnings growth (9.6% per year) is above the savings rate (2.5%).

Kazançlar ve Piyasa: CFB's earnings (9.6% per year) are forecast to grow slower than the US market (15.4% per year).

Yüksek Büyüme Kazançları: CFB's earnings are forecast to grow, but not significantly.

Gelir ve Pazar: CFB's revenue (9.7% per year) is forecast to grow faster than the US market (8.9% per year).

Yüksek Büyüme Geliri: CFB's revenue (9.7% per year) is forecast to grow slower than 20% per year.


Hisse Başına Kazanç Büyüme Tahminleri


Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: CFB's Return on Equity is forecast to be low in 3 years time (9.9%).


Büyüyen şirketleri keşfedin